Exib

Symptomatic relief of OA, RA, ankylosing spondylitis, pain & signs of inflammation associated w/ acute gouty arthritis. Short-term treatment for moderate pain associated w/ dental surgery.

Adult & adolescent ≥16 yr OA 30 mg or 60 mg once daily. Max: 60 mg once daily. RA 60 mg or 90 mg once daily. Max: 90 mg once daily. Ankylosing spondylitis 60 mg or 90 mg once daily. Max: 90 mg once daily. Acute gouty arthritis 120 mg once daily (limited to max of 8 days). Post-op dental surgery pain 90 mg once daily (limited to max of 3 days). Patient w/ mild hepatic impairment (Child-Pugh score 5-6) Max: 60 mg once daily. Patient w/ moderate hepatic impairment (Child-Pugh score 7-9) Max: 30 mg once daily.

May be taken with or without food.

Hypersensitivity. Patients w/ severe heart failure. Treatment of peri-operative pain in CABG surgery setting. Active peptic ulceration or active GI bleeding. Patients who experience bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking ASA or NSAIDs including COX-2 inhibitors. Inflammatory bowel disease. CHF (NYHA II-IV). Patients w/ HTN whose BP is persistently elevated >140/90 mmHg & has not been adequately controlled. Established ischaemic heart disease, peripheral arterial disease, &/or cerebrovascular disease. Severe hepatic impairment (serum albumin <25 g/L or Child-Pugh score ≥10). Estimated renal CrCl <30 mL/min. Pregnancy & lactation. 3rd trimester of pregnancy. Childn & adolescents <16 yr.

Use only for acute symptomatic period in acute pain conditions. Use at the lowest effective dose for the shortest possible time. Increased risk of serious CV thrombotic events, MI, & stroke; serious GI adverse events including bleeding, ulceration, & perforation of the stomach or intestines. Risk of renal papillary necrosis & other renal injury w/ long-term administration. Risk of renal toxicity in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. Not recommended in patients w/ advanced renal disease. Associated w/ serious liver injury in rare cases. Risks of premature closure of the ductus arteriosus & potential to prolong parturition during the 3rd trimester of pregnancy. Caution during the 1st & 2nd trimesters of pregnancy, particularly from middle to end of 2nd trimester (onset at approx 20 wk) due to possible fetal renal dysfunction leading to oligohydramnios &, in some cases, neonatal renal impairment or failure. Not recommended in women attempting to conceive.

Alveolar osteitis; edema/fluid retention; dizziness, headache; palpitations, arrhythmia; HTN; bronchospasm; abdominal pain, constipation, flatulence, gastritis, heartburn/acid reflux, diarrhea, dyspepsia/epigastric discomfort, nausea, vomiting, esophagitis, oral ulcer; increased ALT & AST; ecchymosis; asthenia/fatigue, flu-like disease.

Closely monitor prothrombin time/INR in patients receiving oral anticoagulants, particularly in the 1st few days when etoricoxib is initiated. Reduced effect of diuretics & other antihypertensive drugs (ACE inhibitors or AIIAs). Concomitant administration w/ ASA doses above those for CV prophylaxis or w/ other NSAIDs is not recommended. Increased nephrotoxic effect of cyclosporine or tacrolimus. Decreased renal excretion & increased plasma levels of lithium. Monitor for MTX-related toxicity when etoricoxib & MTX are administered concomitantly. Increased incidence of adverse events associated w/ OCs. Increased risk of adverse events associated w/ HRT. Monitor patients at high risk of digoxin toxicity when etoricoxib & digoxin are administered concomitantly.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.

P₁S₁S₃